Skip to main content

Table 1 Clinical characteristics of the entire study cohort

From: Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers

Characteristic

Training group

Validation group

P

N

84

56

 

Gender, n (%)

  

0.916

Female

35 (25%)

22 (15.7%)

 

Male

49 (35%)

34 (24.3%)

 

BMI (kg/m2), n (%)

  

1.000

18.5–23.9

46 (32.9%)

31 (22.1%)

 

≥24, or <18.5

38 (27.1%)

25 (17.9%)

 

CEA (ug/L), n (%)

  

0.683

≤ 100

81 (57.9%)

53 (37.9%)

 

> 100

3 (2.1%)

3 (2.1%)

 

CA199 (U/mL), n (%)

  

0.626

≤37

73 (52.1%)

51 (36.4%)

 

>37

11 (7.9%)

5 (3.6%)

 

pT, n (%)

  

0.219

T1

14 (10%)

8 (5.7%)

 

T2

19 (13.6%)

14 (10%)

 

T3

42 (30%)

33 (23.6%)

 

T4

9 (6.4%)

1 (0.7%)

 

pN, n (%)

  

0.071

N0

66 (47.1%)

37 (26.4%)

 

N1

11 (7.9%)

16 (11.4%)

 

N2

7 (5%)

3 (2.1%)

 

pTNM, n (%)

  

0.229

Stage I

32 (22.9%)

16 (11.4%)

 

Stage II

34 (24.3%)

21 (15%)

 

Stage III

18 (12.9%)

19 (13.6%)

 

Age (years), mean ± SD

59.39 ± 11.22

60.5 ± 9.69

0.535